L. Yang and A. Ma, “Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation”, FBEM, vol. 8, no. 3, pp. 178–184, Apr. 2023, doi: 10.54097/fbem.v8i3.7835.